A robust classifier of high predictive value to identify good prognosis patients in ER negative breast cancer.
|dc.contributor.author||Teschendorff, Andrew E||en|
|dc.identifier.citation||Breast Cancer Research 2008, 10:R73|
|dc.description.abstract||Abstract Introduction Patients with primary operable oestrogen receptor (ER) negative (-) breast cancer account for about 30% of all cases and generally have a worse prognosis than ER-positive (+) patients. Nevertheless, a significant proportion of ER- cases have favourable outcomes and could potentially benefit from a less aggressive course of therapy. However, identification of such patients with a good prognosis remains difficult and at present is only possible through examining histopathological factors. Methods Building on a previously identified seven-gene prognostic immune response module for ER- breast cancer, we developed a novel statistical tool based on Mixture Discriminant Analysis in order to build a classifier that could accurately identify ER- patients with a good prognosis. Results We report the construction of a seven-gene expression classifier that accurately predicts, across a training cohort of 183 ER- tumours and six independent test cohorts (a total of 469 ER- tumours), ER- patients of good prognosis (in test sets, average predictive value = 94% [range 85 to 100%], average hazard ratio = 0.15 [range 0.07 to 0.36] p < 0.000001) independently of lymph node status and treatment. Conclusions This seven-gene classifier could be used in a polymerase chain reaction-based clinical assay to identify ER- patients with a good prognosis, who may therefore benefit from less aggressive treatment regimens.|
|dc.title||A robust classifier of high predictive value to identify good prognosis patients in ER negative breast cancer.||en|
|dc.description.version||RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.||en|
|dc.rights.holder||Teschendorff et al.; licensee BioMed Central Ltd.|
|dc.contributor.orcid||Caldas, Carlos [0000-0003-3547-1489]|